AIMS/HYPOTHESIS: To validate the reported association between rs10494366 in NOS1AP (the gene encoding nitric oxide synthase-1 adaptor protein) and the incidence of type 2 diabetes in calcium channel blocker (CCB) users and to identify additional NOS1AP variants associated with type 2 diabetes risk. METHODS: Data from 9 years of follow-up in 9,221 middle-aged white and 2,724 African-American adults free of diabetes at baseline from the Atherosclerosis Risk in Communities study were analysed. Nineteen NOS1AP variants were examined for associations with incident diabetes and fasting glucose levels stratified by baseline CCB use. RESULTS: Prevalence of CCB use at baseline was 2.7% (n = 247) in whites and 2.3% (n = 72) in African-Americans. Among white CCB users, the G allele of rs10494366 was associated with lower diabetes incidence (HR 0.57, 95% CI 0.35-0.92, p = 0.016). The association was marginally significant after adjusting for age, sex, obesity, smoking, alcohol use, physical activity, hypertension, heart rate and electrocardiographic QT interval (HR 0.63, 95% CI 0.38-1.04, p = 0.052). rs10494366 was associated with lower average fasting glucose during follow-up (p = 0.037). No other variants were associated with diabetes risk in CCB users after multiple-testing correction. No associations were observed between any NOS1AP variant and diabetes development in non-CCB users. NOS1AP variants were not associated with diabetes risk in either African-American CCB users or non-CCB users. CONCLUSIONS/ INTERPRETATION: We have independently replicated the association between rs10494366 in NOS1AP and incident diabetes among white CCB users. Further exploration of NOS1AP variants and type 2 diabetes and functional studies of NOS1AP in type 2 diabetes pathology is warranted.
AIMS/HYPOTHESIS: To validate the reported association between rs10494366 in NOS1AP (the gene encoding nitric oxide synthase-1 adaptor protein) and the incidence of type 2 diabetes in calcium channel blocker (CCB) users and to identify additional NOS1AP variants associated with type 2 diabetes risk. METHODS: Data from 9 years of follow-up in 9,221 middle-aged white and 2,724 African-American adults free of diabetes at baseline from the Atherosclerosis Risk in Communities study were analysed. Nineteen NOS1AP variants were examined for associations with incident diabetes and fasting glucose levels stratified by baseline CCB use. RESULTS: Prevalence of CCB use at baseline was 2.7% (n = 247) in whites and 2.3% (n = 72) in African-Americans. Among white CCB users, the G allele of rs10494366 was associated with lower diabetes incidence (HR 0.57, 95% CI 0.35-0.92, p = 0.016). The association was marginally significant after adjusting for age, sex, obesity, smoking, alcohol use, physical activity, hypertension, heart rate and electrocardiographic QT interval (HR 0.63, 95% CI 0.38-1.04, p = 0.052). rs10494366 was associated with lower average fasting glucose during follow-up (p = 0.037). No other variants were associated with diabetes risk in CCB users after multiple-testing correction. No associations were observed between any NOS1AP variant and diabetes development in non-CCB users. NOS1AP variants were not associated with diabetes risk in either African-American CCB users or non-CCB users. CONCLUSIONS/ INTERPRETATION: We have independently replicated the association between rs10494366 in NOS1AP and incident diabetes among white CCB users. Further exploration of NOS1AP variants and type 2 diabetes and functional studies of NOS1AP in type 2 diabetes pathology is warranted.
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: Dan E Arking; Arne Pfeufer; Wendy Post; W H Linda Kao; Christopher Newton-Cheh; Morna Ikeda; Kristen West; Carl Kashuk; Mahmut Akyol; Siegfried Perz; Shapour Jalilzadeh; Thomas Illig; Christian Gieger; Chao-Yu Guo; Martin G Larson; H Erich Wichmann; Eduardo Marbán; Christopher J O'Donnell; Joel N Hirschhorn; Stefan Kääb; Peter M Spooner; Thomas Meitinger; Aravinda Chakravarti Journal: Nat Genet Date: 2006-04-30 Impact factor: 38.330
Authors: Kuan-Cheng Chang; Andreas S Barth; Tetsuo Sasano; Eddy Kizana; Yuji Kashiwakura; Yiqiang Zhang; D Brian Foster; Eduardo Marbán Journal: Proc Natl Acad Sci U S A Date: 2008-03-12 Impact factor: 11.205
Authors: M L Becker; L E Visser; C Newton-Cheh; J C M Witteman; A Hofman; A G Uitterlinden; B H Ch Stricker Journal: Diabetologia Date: 2008-09-03 Impact factor: 10.122
Authors: H Duplain; R Burcelin; C Sartori; S Cook; M Egli; M Lepori; P Vollenweider; T Pedrazzini; P Nicod; B Thorens; U Scherrer Journal: Circulation Date: 2001-07-17 Impact factor: 29.690
Authors: Sangeeta R Kashyap; Linda J Roman; Jennifer Lamont; Bettie Sue S Masters; Mandeep Bajaj; Swangjit Suraamornkul; Renata Belfort; Rachele Berria; Dean L Kellogg; Yanjuan Liu; Ralph A DeFronzo Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: R L Hanson; M G Ehm; D J Pettitt; M Prochazka; D B Thompson; D Timberlake; T Foroud; S Kobes; L Baier; D K Burns; L Almasy; J Blangero; W T Garvey; P H Bennett; W C Knowler Journal: Am J Hum Genet Date: 1998-10 Impact factor: 11.025
Authors: David J Margolis; Michelle Hampton; Ole Hoffstad; D Scot Mala; Ziad Mirza; Diana Woltereck; Steven Shannon; Michael A Troiano; Nandita Mitra; Ming Yang; Veena M Bhopale; Stephen R Thom Journal: Wound Repair Regen Date: 2017-08-14 Impact factor: 3.617
Authors: Stephen R Thom; Veena M Bhopale; Kevin Yu; Weiliang Huang; Maureen A Kane; David J Margolis Journal: J Biol Chem Date: 2017-09-25 Impact factor: 5.157